trending Market Intelligence /marketintelligence/en/news-insights/trending/kgeu1gbgqkfngmnsslg9oq2 content esgSubNav
In This List

Aptose to buy China rights to CrystalGenomics' blood cancer drug

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Aptose to buy China rights to CrystalGenomics' blood cancer drug

Aptose Biosciences Inc. signed a licensing deal to develop and commercialize South Korea-based CrystalGenomics Inc.'s blood cancer drug in China, including Hong Kong and Macau.

CG-806 is an investigational treatment for patients with acute myeloid leukemia, B-cell malignancies and other hematologic malignancies. Acute myeloid leukemia is a type of cancer characterized by the bone marrow's production of abnormal myeloblasts, red blood cells or platelets.

Under the agreement, Aptose will give CrystalGenomics US$3 million in an up-front payment. CrystalGenomics will also receive development, regulatory and commercial-based milestone payments, along with single-digit royalties on product sales in the Chinese market, for a total deal value of US$125 million.

The new deal expands Aptose's exclusive license to develop and commercialize CG-806 globally, except Korea.